S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
Log in

CVE:COT - Cotinga Pharmaceuticals Stock Price, Forecast & News

C$0.06
-20,006.94 (-100.00 %)
(As of 03/30/2020 04:00 PM ET)
Today's Range
C$0.07
Now: C$0.07
C$0.07
50-Day Range
C$0.02
MA: C$0.06
C$0.08
52-Week Range
C$0.02
Now: C$0.07
C$0.37
Volume17,000 shs
Average Volume24,079 shs
Market CapitalizationC$1.43 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Cotinga Pharmaceuticals Inc., a biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, a clinical stage oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. was founded in 1999 and is based in Boston, Massachusetts.
Read More

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-519-8585157

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Cash FlowC$0.00 per share
Book ValueC($0.15) per share

Profitability

Miscellaneous

EmployeesN/A
Market CapC$1.43 million
Next Earnings Date4/6/2020 (Estimated)
OptionableOptionable

Receive COT News and Ratings via Email

Sign-up to receive the latest news and ratings for COT and its competitors with MarketBeat's FREE daily newsletter.


Cotinga Pharmaceuticals (CVE:COT) Frequently Asked Questions

How has Cotinga Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Cotinga Pharmaceuticals' stock was trading at C$0.03 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, COT shares have increased by 116.7% and is now trading at C$0.07. View which stocks have been mosted impacted by Coronavirus.

When is Cotinga Pharmaceuticals' next earnings date?

Cotinga Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, April 6th 2020. View our earnings forecast for Cotinga Pharmaceuticals.

Has Cotinga Pharmaceuticals been receiving favorable news coverage?

Media coverage about COT stock has been trending very negative recently, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cotinga Pharmaceuticals earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutCotinga Pharmaceuticals.

Who are some of Cotinga Pharmaceuticals' key competitors?

What other stocks do shareholders of Cotinga Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cotinga Pharmaceuticals investors own include Primo Water (PRMW), Aurora Cannabis (ACB), Cascades (CAS), Exchange Income (EIF), Alimentation Couche-Tard (ATD.B), Aecon Group (ARE), Canadian National Railway (CNI), Harvest One Cannabis (HVT), Datametrex AI (DM) and American Manganese (AMY).

Who are Cotinga Pharmaceuticals' key executives?

Cotinga Pharmaceuticals' management team includes the following people:
  • Ms. Alison D. Silva, CEO, Pres & Director
  • Dr. Richard T. Ho, Chief Scientific Officer (Age 56)
  • Mr. Victor Hugo, Chief Financial Officer (Age 51)
  • Ms. Debi Sanderson MBA, Director of Resourcing & Operations
  • Mr. Paul Papi, VP of Investor Relations

What is Cotinga Pharmaceuticals' stock symbol?

Cotinga Pharmaceuticals trades on the Canadian Venture Exchange (CVE) under the ticker symbol "COT."

How do I buy shares of Cotinga Pharmaceuticals?

Shares of COT and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is Cotinga Pharmaceuticals' stock price today?

One share of COT stock can currently be purchased for approximately C$0.07.

How big of a company is Cotinga Pharmaceuticals?

Cotinga Pharmaceuticals has a market capitalization of C$1.43 million.  View additional information about Cotinga Pharmaceuticals.

What is Cotinga Pharmaceuticals' official website?

The official website for Cotinga Pharmaceuticals is http://cotingapharma.com/.

How can I contact Cotinga Pharmaceuticals?

Cotinga Pharmaceuticals' mailing address is 100 Collip Cir Suite 230B, LONDON, ON N6G 4X8, Canada. The company can be reached via phone at +1-519-8585157.


MarketBeat Community Rating for Cotinga Pharmaceuticals (CVE COT)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  100 (Vote Outperform)
Underperform Votes:  83 (Vote Underperform)
Total Votes:  183
MarketBeat's community ratings are surveys of what our community members think about Cotinga Pharmaceuticals and other stocks. Vote "Outperform" if you believe COT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe COT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/30/2020 by MarketBeat.com Staff

Featured Article: Strangles

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel